BTIG analyst Jeet Mukherjee maintained a Buy rating on Monopar Therapeutics Inc yesterday and set a price target of $104.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jeet Mukherjee has given his Buy rating due to a combination of factors that highlight both the medical importance and commercial potential of ALXN1840 in Wilson’s disease. Feedback from the recent FDA patient-focused meeting underscored substantial unmet needs, including more convenient dosing, fewer side effects, and better control of neurological symptoms—areas where ALXN1840 appears well suited, given its once-daily oral regimen, long-term safety data, and evidence of robust copper removal from tissues. Compelling patient testimonials describing dramatic neurological improvement and life-changing benefits strengthen the case that ALXN1840 offers a meaningful advance over existing options, and they directly support MNPR’s regulatory story ahead of the planned NDA submission in the first half of 2026.
At the same time, current standard-of-care treatments for Wilson’s disease remain burdened by complex schedules, fasting constraints, tolerability problems, and incomplete symptom control, which reinforces the potential for ALXN1840 to gain traction if approved. Mukherjee also notes that MNPR has been actively de‑risking the regulatory path by addressing prior copper balance concerns with new analyses indicating significant negative copper balance and increased fecal copper excretion, and by engaging experienced regulatory consultants, including a former senior regulatory leader from Moderna. With the recent patient meeting likely to positively influence FDA perception, a plausible early 2027 approval timeline, and a discounted cash flow valuation that supports upside, he concludes that the risk/reward profile favors a Buy rating on MNPR shares.
According to TipRanks, Mukherjee is a 4-star analyst with an average return of 24.3% and a 62.75% success rate. Mukherjee covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, Aardvark Therapeutics, Inc., and Monopar Therapeutics Inc.
In another report released on January 30, Barclays also maintained a Buy rating on the stock with a $125.00 price target.